Targeted Medical Pharma, Inc.
TRGM · OTC
12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | |
|---|---|---|---|---|
| Market Cap | $0 | $5 | $18 | $55 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $5 | $4 | $5 | $5 |
| Enterprise Value | $6 | $9 | $22 | $60 |
| Revenue | $5 | $7 | $10 | $7 |
| % Growth | -26% | -25.6% | 31% | – |
| Gross Profit | $3 | $5 | $7 | $4 |
| % Margin | 60.2% | 68.8% | 68.7% | 56.1% |
| EBITDA | -$2 | -$2 | -$3 | -$10 |
| % Margin | -31.6% | -30.9% | -35.9% | -138.9% |
| Net Income | -$3 | -$4 | -$9 | -$10 |
| % Margin | -57.9% | -54.8% | -97.7% | -131.4% |
| EPS Diluted | -0.11 | -0.15 | -0.39 | -0.43 |
| % Growth | 26.7% | 61.5% | 9.3% | – |
| Operating Cash Flow | -$1 | $1 | -$2 | -$2 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$1 | $1 | -$2 | -$3 |